The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The End Stage Renal Disease (ESRD) Drug Market Expected To Change Between 2026 And 2030?
The end stage renal disease (ESRD) drug market size has expanded significantly in recent years. It is expected to grow from $148.55 billion in 2025 to $171.12 billion in 2026, at a compound annual growth rate (CAGR) of 15.2%. The expansion observed in the past can be attributed to the rising prevalence of CKD, increased awareness of ESRD, an uptick in dialysis centers, developments in renal therapeutics, and various government healthcare initiatives.
The end stage renal disease (esrd) drug market size is anticipated to undergo significant expansion in the coming years, with projections indicating a growth to $304.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.5%. This growth throughout the forecast period is propelled by factors such as the progression of precision medicine, the broader accessibility of homecare dialysis, the incorporation of AI in tracking patient health, increasing financial commitments to ESRD research and development, and the increasing adoption of combination therapies. Prominent trends for this period are expected to encompass personalized ESRD drug treatments, solutions for home-based dialysis, the integration of telemedicine into CKD management, advanced drug formulations to address secondary complications, and a continued rise in the utilization of combination therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Which Major Factors Are Driving The Expansion Of The End Stage Renal Disease (ESRD) Drug Market?
The increasing prevalence of obesity and diabetes is anticipated to stimulate the expansion of the end-stage renal disease (ESRD) drug market in the future. Obesity is defined as an unusual or excessive accumulation of body fat that presents health risks. Conversely, diabetes is a long-term ailment that occurs when the pancreas fails to produce sufficient insulin or when the body is unable to effectively use the insulin it generates. For individuals with renal disease, controlling fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis can enhance overall health and well-being, potentially resulting in weight loss and better blood sugar management. For example, in 2023, the World Obesity Federation, a non profit membership organization, predicted that by 2035, the annual economic burden of overweight and obesity would reach US$ 4.32 trillion, representing almost 3% of global. Moreover, in June 2024, data from the National Health Service, a UK-based government department, showed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state with elevated blood sugar levels, not severe enough to be classified as diabetes) in 2023, indicating an 18% increase from 3,065,825 cases in 2022. Consequently, the growing instances of obesity and diabetes will propel the market for end-stage renal disease (ESRD) drugs.
How Is The End Stage Renal Disease (ESRD) Drug Market Structured Across Different Segments?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
Which Trends Are Shaping The Future Of The End Stage Renal Disease (ESRD) Drug Market?
Leading companies in the end-stage renal disease (ESRD) drug market are concentrating on product approvals, such as Jardiance, to enhance their market revenues. Empagliflozin is a medication formulated to aid individuals with type 2 diabetes and to lessen the probability of cardiovascular issues in persons with type 2 diabetes who also suffer from heart failure or cardiovascular disease. For instance, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical entity, received FDA approval for Jardiance. Jardiance has been sanctioned for several indications, including the reduction of risk for end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, along with decreasing the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults experiencing heart failure. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, Jardiance is contraindicated in patients with type 1 diabetes and those whose eGFR is less than 20 ml/min/1.73 m.
Which Major Players Dominate The End Stage Renal Disease (ESRD) Drug Market?
Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Read the full end stage renal disease (esrd) drug market report here:
Which Region Currently Holds The Largest Share Of The End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored End Stage Renal Disease (ESRD) Drug Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp
Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2026, By The Business Research Company
End Stage Renal Disease Esrd Drug Market Report 2026
Late Stage Chronic Kidney Disease Drugs Market Report 2026
Kidney Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model